Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 33-39

  Leitner, Wolfgang W ^a   Hwang, Leroy N ^a   De Veer, Michael J ^b   Zhou, Aimin ^c   Silverman, Robert H ^b   Williams, Bryan R G ^b   Dubensky, Thomas W ^d   Ying, Han ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CLEVELAND STATE UNIVERSITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; DNA VACCINE; DOUBLE STRANDED RNA; MESSENGER RNA; OLIGOADENYLATE SYNTHETASE; PROTEIN KINASE; PROTEIN KINASE R; RIBONUCLEASE; SYNTHETASE; TYROSINASE RELATED PROTEIN 1; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MELANOMA; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REPLICON; RNA SYNTHESIS; TUMOR CELL; TUMOR IMMUNITY;

ALPHAVIRUS; ANIMALS; CANCER VACCINES; GENE TRANSFER TECHNIQUES; GENES, REPORTER; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOTHERAPY; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OXIDOREDUCTASES; PLASMIDS; PROTEINS; REPLICON; RNA REPLICASE; RNA, DOUBLE-STRANDED; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINES, DNA;

ALPHAVIRUS; ANIMALIA;

EID: 0037236237     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm813     Document Type: Article

References (46)

1. Yewdell, J.W. & Bennink, J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999).
2. Blum, J.S., Ma, C. & Kovats, S. Antigen-presenting cells and the selection of immunodominant epitopes. Crit. Rev. Immunol. 17, 411-417 (1997).
3. Donnelly, J.J., Ulmer, J.B., Shiver, J.W. & Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 15, 617-648 (1997).
4. Leitner, W.W., Hammerl, P. & Thalhamer, J. Nucleic acid for the treatment of cancer: Genetic vaccines and DNA adjuvants. Curr. Pharm. Res. 7, 1641-1667 (2001).
5. Sasaki, S., Amara, R.R., Oran, A.E., Smith, J.M. & Robinson, H.L. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nature Biotechnol. 19, 543-547 (2001).
6. Zhou, X. et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12, 1510-1514 (1994).
7. Herweijer, H. et al. A plasmid-based self-amplifying Sindbis virus vector. Hum. Gene Ther. 6, 1161-1167 (1995).
8. Schlesinger, S. Alphavirus vectors: Development and potential therapeutic applications. Exp. Opin. Biol. Ther. 1, 177-191 (2001).
9. Schlesinger, R.W. in The Togaviruses (ed. Wengler, G.) 459 (Academic Press, New York, 1980).
10. Hariharan, M.J. et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 72, 950-958 (1998).
11. Berglund, P., Smerdou, C., Fleeton, M.N., Tubulekas, I. & Liljestrom, P. Enhancing immune responses using suicidal DNA vaccines. Nature Biotechnol. 16, 562-565 (1998).
12. Leitner, W.W., Ying, H., Driver, D.A., Dubensky, T.W. & Restifo, N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60, 51-55 (2000).
13. Weber, L.W. et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102, 1258-1264 (1998).
14. Zhou, A., Hassel, B.A. & Silverman, R.H. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72, 753-765 (1993).
15. Overwijk, W.W. et al. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277-286 (1998).
16. Bowne, W.B. et al. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190, 1717-1722 (1999).
17. Ying, H. et al. Cancer therapy using a self-replicating RNA vaccine. Nature Med. 5, 823-827 (1999).
18. Vijayasaradhi, S., Bouchard, B. & Houghton, A.N. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J. Exp. Med. 171, 1375-1380 (1990).
19. Ito, S. & Jimbow, K. Quantitative analysis of eumelanin and pheomelanin in hair and melanomas. J. Invest. Dermatol. 80, 268-272 (1983).
20. Overwijk, W.W. et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982-2987 (1999).
21. Player, M.R. & Torrence, P.F. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. 78, 55-113 (1998).
22. Williams, B.R. PKR; a sentinel kinase for cellular stress. Oncogene 18, 6112-6120 (1999).
23. Terenzi, F. et al. The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors. Nucleic Acids Res. 27, 4369-4375 (1999).
24. Zhou, A. et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J. 16, 6355-6363 (1997).
25. van Elsas, A. et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J. Exp. Med. 194, 481-489 (2001).
26. Leitner, W.W., Ying, H. & Restifo, N.P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18, 765-777 (1999).
27. Dubensky, T.W.J. et al. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70, 508-519 (1996).
28. Johanning, F.W. et al. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res. 23, 1495-1501 (1995).
29. Sasaki, S. et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect. Immun. 65, 3520-3528 (1997).
30. Perri, S. et al. Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells. J. Virol. 74, 9802-9807 (2000).
31. Albert, M.L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
32. Chen, Z. et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer 93, 539-548 (2001).
33. Shaif-Muthana, M., McIntyre, C., Sisley, K., Rennie, I. & Murray, A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res. 60, 6441-6447 (2000).
34. Restifo, N.P. Vaccines to die for. Nature Biotechnol. 19, 527-528 (2001).
35. Chattergoon, M.A. et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nature Biotechnol. 18, 974-979 (2000).
36. Der, S.D., Yang, Y.L., Weissmann, C. & Williams, B.R. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. USA 94, 3279-3283 (1997).
37. Sarid, R., Sato, T., Bohenzky, R.A., Russo, J.J. & Chang, Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nature Med. 3, 293-298 (1997).
38. Revilla, Y. et al. Inhibition of apoptosis by the African swine fever virus Bcl-2 homologue: Role of the BH1 domain. Virology 228, 400-404 (1997).
39. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652-656 (1998).
40. Wagner, H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 5, 62-69 (2002).
41. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732-738 (2001).
42. Surman, D.R. et al. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J. Immunol. Methods 214, 51-62 (1998).
43. Leitner, W.W. et al. Immune responses induced by intramuscular or gene gun injection of protective DNA vaccines that express circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 157, 6119 (1997).
44. Touloukian, C.E. et al. Expression of a "self"-antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 62, 5144-5147 (2002).
45. Xu, Z. & Williams, B.R. The B56α regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mot. Cell. Biol. 20, 5285-5299 (2000).
46. Kumar, A., Haque, J., Lacoste, J., Hiscott, J. & Williams, B.R. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating 1 κ B. Proc. Natl. Acad. Sci. USA 91, 6288-6292 (1994).